The current study investigated whether, for spatial reference memory, age impacts (1) sensitivity to surgical ovarian hormone loss (Ovx), (2) response to estradiol therapy (ET), and (3) the relation between circulating estradiol levels and memory scores in ovary-intact sham and Ovx plus ET rats. Young, middleaged and aged Fischer-344 rats received sham, Ovx or Ovx plus ET treatments, and were then tested on the Morris maze. After the last test trial, a probe trial was given whereby the platform was removed. Circulating estradiol levels were then determined and correlated with performance. In Study 1, Ovx facilitated learning on day one, but impaired performance after day one, in young rats. Ovx did not influence performance in middle-aged rats. In young and middle-aged Ovx rats, ET enhanced performance with higher exogenous estradiol levels correlating with better performance during testing and the probe trial. There was no relationship between endogenous estradiol levels and performance in sham young or middle-aged rats. Study 2 showed that, like middle-aged rats, aged rats were not impacted by Ovx. Further, for aged Ovx rats, the ET regimen that was beneficial at earlier ages was no longer effective during test trials, and had only minor benefits for platform localization as assessed by the probe trial. Collectively, the findings suggest that the effects of Ovx as well as responsivity to the currently utilized ET regimen changes with age. Further, there appears to be a distinction between sensitivity to Ovx and responsiveness to ET after Ovx for spatial reference memory performance.
Introduction
There is abundant clinical and basic science evidence that estrogens impact cognitive function (Dohanich, 2002) . Since the first controlled clinical evaluation showing that estrogen injections given to 75-year-old women enhanced memory (Caldwell & Watson, 1952) , there have been numerous studies showing cognitive decline after ovarian hormone loss, and enhancement after estrogen replacement, in menopausal women (Sherwin, 2006) . However, several newer clinical studies, including the large, placebo-controlled, multi-center Women's Health Initiative Memory Study, have indicated that certain regimens of hormone treatment, for example, use of conjugated equine estrogens with or without medroxyprogesterone, can have null or detrimental effects on cognition and dementia risk in women (Mulnard et al., 2000; Rapp, Morrison, & Roberts, 2003; Shumaker et al., 2003 Shumaker et al., , 2004 Wang et al., 2000) .
The majority of the animal studies evaluating the activational effects of estrogens on learning and memory have been performed in young rodents (Bimonte & Denenberg, 1999; Daniel, Fader, Spencer, & Dohanich, 1997; Daniel, Roberts, & Dohanich, 1999; Dohanich, Fader, & Javorsky, 1994; Galea et al., 2001; Holmes, Wide, & Galea, 2002; Luine, Jacome, & Maclusky, 2003; Luine, Richards, Wu, & Beck, 1998; Marriott & Korol, 2003; Packard & Teather, 1997; Sandstrom & Williams, 2001; Singh, Meyer, Millard, & Simpkins, 1994) . While there has been a recent increase in the number of studies evaluating estrogen effects in middle-aged or older female rodents, most using the most potent estrogen, estradiol (Bimonte-Nelson, Francis, Umphlet, & Granholm, 2006; Foster, Sharrow, Kumar, & Masse, 2003; Frick, Fernandez, & Bulinski, 2002; Gibbs, 2000; Luine & Rodriguez, 1994; Markham, Pych, & Juraska, 2002; Markowska & Savonenko, 2002a; Savonenko & Markowska, 2003; Ziegler & Gallagher, 2005) , there is only limited work comparing estrogen replacement effects in ovariectomized (Ovx) animals at different ages within the same study (Foster et al., 2003) . Hence, it is still a question whether age changes responsiveness to ovarian hormone replacement. This is a clinically important question, as some menopausal women begin hormone
